Tuesday, January 12, 2010 9:17:57 AM
7:02AM BioCryst Pharm and moksha8 announce approval for the importation & use of peramivir in Mexico (BCRX) 8.17 : Co announces that moksha8 has been granted approval from The Federal Commission for the Protection against Sanitary Risk in Mexico for the importation and use of peramivir in patients with influenza associated with the 2009 H1N1 influenza A strain. moksha8 has informed BioCryst that it has also filed for regulatory approval of peramivir in Brazil.
Recent BCRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:07:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:48:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:08:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2026 05:06:28 PM
- BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 • GlobeNewswire Inc. • 05/13/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:06:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:08:17 AM
- BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 11:06:53 AM
- BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:02:16 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:10:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:02:30 PM
- BioCryst to Report First Quarter 2026 Financial Results on May 6 • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 08:24:44 PM
- BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer • GlobeNewswire Inc. • 04/06/2026 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:02:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/20/2026 03:36:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:11:09 PM

